- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2012 (2012), Article ID 492578, 8 pages
Detection of PIK3CA Mutations in Breast Cancer Bone Metastases
1Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
2Department of Pathology, Ottawa Hospital, Ottawa, Canada K1H 8L6
3Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada K1H 8M5
4Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada K1H 8M5
Received 28 May 2012; Accepted 25 June 2012
Academic Editors: G. E. Lind, V. Lorusso, and R. Nahta
Copyright © 2012 Manijeh Daneshmand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. P. Shah, R. D. Morin, J. Khattra et al., “Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution,” Nature, vol. 461, no. 7265, pp. 809–813, 2009.
- S. Yachida, S. Jones, I. Bozic et al., “Distant metastasis occurs late during the genetic evolution of pancreatic cancer,” Nature, vol. 467, no. 7319, pp. 1114–1117, 2010.
- B. Karakas, K. E. Bachman, and B. H. Park, “Mutation of the PIK3CA oncogene in human cancers,” British Journal of Cancer, vol. 94, no. 4, pp. 455–459, 2006.
- L. Zhao and P. K. Vogt, “Class I PI3K in oncogenic cellular transformation,” Oncogene, vol. 27, no. 41, pp. 5486–5496, 2008.
- R. J. Crowder, C. Phommaly, Y. Tao et al., “PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer,” Cancer Research, vol. 69, no. 9, pp. 3955–3962, 2009.
- A. G. Bader, S. Kang, and P. K. Vogt, “Cancer-specific mutations in PIK3CA are oncogenic in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1475–1479, 2006.
- A. G. Bader, S. Kang, L. Zhao, and P. K. Vogt, “Oncogenic PI3K deregulates transcription and translation,” Nature Reviews Cancer, vol. 5, no. 12, pp. 921–929, 2005.
- J. D. Jensen, A. V. Laenkholm, A. Knoop et al., “PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer,” Clinical Cancer Research, vol. 17, no. 4, pp. 667–677, 2011.
- K. Kalinsky, A. Heguy, U. K. Bhanot, S. Patil, and M. E. Moynahan, “PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression,” Breast Cancer Research and Treatment, vol. 129, pp. 635–643, 2011.
- A. M. Gonzalez-Angulo, J. Ferrer-Lozano, K. Stemke-Hale et al., “PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer,” Molecular Cancer Therapeutics, vol. 10, no. 6, pp. 1093–1101, 2011.
- J. F. Hilton, E. Amir, S. Hopkins et al., “Acquisition of metastatic tissue from patients with bone metastases from breast cancer,” Breast Cancer Research and Treatment, vol. 129, no. 3, pp. 761–765, 2010.
- F. B. Dean, S. Hosono, L. Fang et al., “Comprehensive human genome amplification using multiple displacement amplification,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 8, pp. 5261–5266, 2002.
- K. Kalinsky, L. M. Jacks, A. Heguy et al., “PIK3CA mutation associates with improved outcome in breast cancer,” Clinical Cancer Research, vol. 15, no. 16, pp. 5049–5059, 2009.
- E. Amir, N. Miller, W. Geddie, O. Freedman, F. Kassam, and C. Simmons, “Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer,” Journal of Clinical Oncology, vol. 30, no. 6, pp. 587–592, 2012.
- V. Serra, B. Markman, M. Scaltriti et al., “NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations,” Cancer Research, vol. 68, no. 19, pp. 8022–8030, 2008.
- E. Leung, J. E. Kim, G. W. Rewcastle, G. J. Finlay, and B. C. Baguley, “Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells,” Cancer Biology and Therapy, vol. 11, no. 11, pp. 938–946, 2011.
- C. G. Sanchez, C. X. Ma, R. J. Crowder et al., “Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer,” Breast Cancer Research, vol. 13, no. 2, article R21, 2011.
- A. Chakrabarty, V. Sanchez, M. G. Kuba, C. Rinehart, and C. L. Arteaga, “Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 2718–2723, 2012.